Neurocrine Biosciences (NBIX) is in focus after new real world clinician survey data on INGREZZA for mild tardive dyskinesia highlighted improvements in uncontrolled movements, daily functioning, independence and work or school participation.

The fresh real world INGREZZA data lands while Neurocrine Biosciences’ share price sits at US$154.67, with a 30 day share price return of 17.54% and a 1 year total shareholder return of 28.29%, pointing to momentum that has built over several years.

If this INGREZZA update has you thinking about other specialist healthcare opportunities, it could be worth scanning for companies at the intersection of medicine and AI using our 30 healthcare AI stocks

With Neurocrine’s share price near US$154.67, alongside recent gains and strong reported earnings, the key question is whether today’s valuation still leaves upside on the table or if the market is already pricing in future growth.

Most Popular Narrative: 17% Undervalued

At a last close of US$154.67 versus a narrative fair value of US$186.45, the most followed view sees meaningful upside still tied to execution on key products and the broader pipeline.

Sustained strong volume growth of flagship product INGREZZA, driven by increased payer access initiatives, expanded sales force efforts, and ongoing under-diagnosis in the target population, positions the franchise for multi-year revenue and market share expansion.

Curious what earnings path needs to support that valuation gap? The narrative leans on faster profit growth than revenue and a richer future earnings multiple. The exact mix of margin expansion and revenue compounding is where the story gets interesting.

Result: Fair Value of $186.45 (UNDERVALUED)

However, investors still need to watch for pricing pressure on INGREZZA and heavier payer scrutiny, which could weigh on margins and make future earnings less predictable.

Another Angle on Valuation

The SWS fair ratio for Neurocrine points to a P/E of 23.9x, very close to the current 23.3x. That is higher than both peer companies at 20.8x and the wider US Biotechs group at 16x. Are investors already paying up for execution, or is this just the going rate for quality growth?

See what the numbers say about this price gap in our valuation breakdown by checking the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With the recent tone leaning optimistic, it makes sense to review the underlying data yourself and move quickly to form your own view, including how the company stacks up on 4 key rewards.

Looking for more investment ideas?

If Neurocrine has sharpened your focus, do not stop here. The next step could be lining up a few more stocks that match your style.

• Target potential mispricing by scanning a curated set of companies trading below fair value using the 51 high quality undervalued stocks.
• Prioritise resilience by reviewing companies that pass strict balance sheet and fundamentals checks through the solid balance sheet and fundamentals stocks screener (46 results).
• Spot underfollowed opportunities by tapping into a screener containing 21 high quality undiscovered gems before other investors start paying attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.